Open an account

Tandem Diabetes Care

TNDM · NASDAQ

$16.52+$0.14 (+0.85%)TodayMarket closed ·
Prev close $16.38

About TNDM

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,500 full-time employees. The company went IPO on 2013-11-13. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.

Employees
2,500
Headquarters
San Diego, California
Listed
Nov 13, 2013
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
tandemdiabetes.com

TNDM key statistics

Market cap
1.14B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.23M
Volume
1.59M
Open price
$16.47
High today
$16.87
Low today
$16.37
52 Week high
$29.65
52 Week low
$12.26

Tandem Diabetes Care (TNDM) at a glance

Tandem Diabetes Care (TNDM) last traded at $16.52, with a market cap of 1.14B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $16.37 and $16.87. The current price is 0.9% above the day's low and 2.0% below its high.

Volume so far is 1.59M shares, below the average of 2.23M shares a day.

Over the past year Tandem Diabetes Care has ranged from $12.26 to $29.65, and now sits 24% of the way up that range.

Tandem Diabetes Care met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.31 per share against an estimate of -$0.3261.

The average analyst price target is $29.37, 77.8% above the current price, from 21 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

48%of 21 analyst ratings say Buy
  • Buy47.6%
  • Hold52.4%
  • Sell0.0%
Price target · 21 analystsAvg $29.37
Low
$18.18
Now
$16.52
High
$52.50

TNDM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 41.6% on average.

  1. Q3 FY24: reported -$0.35 per share against an estimate of -$0.4136
  2. Q4 FY24: reported $0.01 per share against an estimate of -$0.2342
  3. Q1 FY25: reported -$0.66 per share against an estimate of -$0.6245
  4. Q2 FY25: reported -$0.484 per share against an estimate of -$0.4079
  5. Q3 FY25: reported -$0.31 per share against an estimate of -$0.3202
  6. Q4 FY25: reported -$0.01 per share against an estimate of -$0.0839
  7. Q1 FY26: reported -$0.30 per share against an estimate of -$0.4532
  8. Q2 FY26: reported -$0.31 per share against an estimate of -$0.3261

TNDM news

  • Press releaseBusiness Wire

    Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026

  • Press releaseBusiness Wire

    Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets

  • Vandana Singh

    FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

  • Vandana Singh

    Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

  • Press releaseBusiness Wire

    Tandem Diabetes Care Announces Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Tandem Diabetes Care Announces Upcoming Conference Presentation

  • Press releaseBusiness Wire

    Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets

  • Press releaseBusiness Wire

    Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026

Similar companies

Companies in the same industry as Tandem Diabetes Care

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.